Cilostazol is a novel antiplatelet inhibitor with vasodilatory effects. It can reduce the degradation of cAMP by inhibiting phosphodiesterase activity, thereby increasing the levels of cAMP in platelets and blood vessels, inhibiting platelet aggregation and dilating blood vessels. Clinically, it is primarily used to alleviate ischemic symptoms such as ulcers, limb pain, cold sensations, and intermittent claudication etc. caused by chronic arterial occlusion. In multiple randomized controlled trials and analyses, Cilostazol has been shown to effectively prevent cerebral infarction.

With many years of exceptional production capabilities, Huayi has earned the trust of customers. We always adhere to strict standards and requirements to ensure compliance of drug manufacturing process and controllable drug quality, meeting the rigorous demands of our customers. Our close collaboration with Muyuan Pharma, based on our shared vision and solid foundation of trust, has successfully led to the product approved by the NMPA! Looking forward to more cooperation with Muyuan Pharma in the future.

Huayi will be continuously dedicated to the pharmaceutical field and consistently provides our customers with high-efficient, high-quality, cost-controllable, and trustworthy R&D and manufacture services to assist customer to get their products approved and marketed!